Special Issue

Gastric Cancer: Innovations in Screening, Diagnosis and Treatment

Message from the Guest Editors

Gastric cancer remains a particularly lethal disease, having the fourth highest fatality rate and the fifth highest incidence rate worldwide. This malignancy shows its symptoms in advanced stages. Therefore, one of the challenging issues regarding gastric cancer is the screening and diagnosis of these advanced stages, which causes a weak prognosis in patients with gastric malignancies. Research into various methods of early screening and diagnosis of gastric cancer, as well as new treatment options, is important for improving the prognosis. A better understanding of the different aspects of this disease could save millions of lives worldwide. Given the importance of the early diagnosis and treatment of gastric malignancies, this Special Issue aims to bring together research that helps us to understand the innovations in screening, diagnosis, and treatment of gastric cancer. This has an important role in the development of gastric cancer. Original research articles and reviews are welcome. Research areas may include (but are not limited to) all the aforementioned topics.

Guest Editors

Dr. Wenhong Deng
Department of General Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, China

Dr. Jun He
Department of General Surgery, The Second Xiangya Hospital, Central South University, Changsha 410011, China

Deadline for manuscript submissions

closed (5 June 2023)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 4.1
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

About the Journal

Message from the Editorial Board

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editors-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:
indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:
CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).